Search Results - "P BALASUBRAMANIAN, VIJAY"

Participation in pulmonary hypertension support group improves patient-reported health quality outcomes: a patient and caregiver survey by Giri, Paresh C., Stevens, Gizelle J., Merrill-Henry, Jeanette, Oyoyo, Udochukwu, Balasubramanian, Vijay P.

“…Support group participation has been shown to be effective in many chronic medical conditions. The evidence for integrating support group into pulmonary…”
Get full text

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting by Balasubramanian, Vijay P., Safdar, Zeenat, Sketch, Margaret R., Broderick, Meredith, Nelsen, Andrew C., Lee, Dasom, Melendres‐Groves, Lana

“…Real‐world dosing and titration of parenteral (subcutaneous, SC; intravenous, IV) prostacyclin, a mainstay of pulmonary arterial hypertension (PAH) treatment,…”
Get full text

Real-world experience with riociguat as potential bridging therapy in patients with chronic thromboembolic pulmonary hypertension: a case series by Balasubramanian, Vijay P., Beutner, Matthew, Gill, Kirat, Kakol, Monika, Melendres-Groves, Lana

Get full text

Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat by Rahaghi, Franck F., Balasubramanian, Vijay P., Bourge, Robert C., Burger, Charles D., Chakinala, Murali M., Eggert, Michael S., Elwing, Jean M., Feldman, Jeremy, King, Christopher, Klinger, James R., Mathai, Stephen C., McConnell, John Wesley, Palevsky, Harold I., Restrepo‐Jaramillo, Ricardo, Safdar, Zeenat, Sager, Jeffrey S., Sood, Namita, Sulica, Roxana, White, R. James, Hill, Nicholas S.

“…Dual combination therapy with a phosphodiesterase‐5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with…”
Get full text

Dosing characteristics of oral treprostinil in real-world clinical practice by Balasubramanian, Vijay P., Messick, Chad R., Broderick, Meredith, Nelsen, Andrew C.

“…Pharmacokinetic studies with oral treprostinil demonstrate that three times daily (TID) dosing reduces peak-to-trough plasma trepostinil fluctuations compared…”
Get full text

Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation by Rahaghi, Franck F., Feldman, Jeremy P., Allen, Roblee P., Tapson, Victor, Safdar, Zeenat, Balasubramanian, Vijay P., Shapiro, Shelley, Mathier, Michael A., Elwing, Jean M., Chakinala, Murali M., White, R. James

“…Oral treprostinil was recently labeled for treatment of pulmonary arterial hypertension. Similar to the period immediately after parenteral treprostinil was…”
Get full text

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document by Rahaghi, Franck F., Alnuaimat, Hassan M., Awdish, Rana L.A., Balasubramanian, Vijay P., Bourge, Robert C., Burger, Charles D., Butler, John, Cauthen, C. Gregory, Chakinala, Murali M., deBoisblanc, Bennett P., Eggert, Michael S., Engel, Peter, Feldman, Jeremy, McConnell, J. Wesley, Park, Myung, Sager, Jeffrey S., Sood, Namita, Palevsky, Harold I.

“…In patients treated with macitentan (Opsumit®, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or…”
Get full text

An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil by Rahaghi, Franck F., Allen, Roblee P., Balasubramanian, Vijay P., Chakinala, Murali M., Elwing, Jean M., Feldman, Jeremy, Leary, Peter J., Rischard, Franz, Safdar, Zeenat, Sood, Namita, Oudiz, Ronald J.

“…Treprostinil, a prostacyclin analogue used in the treatment of pulmonary arterial hypertension (PAH), is available for administration by parenteral, oral, or…”
Get full text

Chronic obstructive pulmonary disease: effects beyond the lungs by Balasubramanian, Vijay P, Varkey, Basil

“…PURPOSE OF REVIEWThis article reviews the systemic effects of chronic obstructive pulmonary disease in general and the musculoskeletal effects and cachexia in…”
Get full text

A BIZARRE COMPLICATION OF CHRONIC MITRAL REGURGITATION: UNILATERAL PULMONARY FIBROSIS by ABDULNOUR, TATIANA, HOLM, DAVID, CROSSWHITE, BROOKE, RIZVI, BISHARAH S, BALASUBRAMANIAN, VIJAY P

Get full text

Pneumocystis carinii pneumonia with pleural effusion in a non-HIV host by Balasubramanian, Vijay P, Komorowski, Richard A, Santo Tomas, Linus H

“…Pneumocystis carinii pneumonia (PCP) is a life-threatening opportunistic infection that occurs in immunocompromised hosts, especially patients with the…”
Get full text

Cystic and Solid Brain Metastases in a Patient With Small Cell Lung Carcinoma by Balasubramanian, Vijay P, Kocak, Mehmet, Schapira, Ralph M

“…Brain metastases occur in 25%–35% of all cancer patients. The majority of brain metastases are solid tumors; cystic brain metastases are unusual. Several…”
Get full text

ORAL TREPROSTINIL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN PULMONARY ARTERIAL HYPERTENSION PARTICIPANTS IN FREEDOM-EV AND THE FREEDOM-EV OPEN-LABEL EXTENSION STUDY by WHITE, R. JAMES, PEPKE-ZABA, JOANNA, P BALASUBRAMANIAN, VIJAY, M. ELWING, JEAN, MC VONK, MADELON, H. ROSENKRANZ, STEPHAN, CADARET, LINDA M, SAHAY, SANDEEP, YU, ZAIXIN, HOLDSTOCK, LOUIS, DENG, C.Q., SEAMAN, SCOTT, BRODERICK, MEREDITH, DV VIZZA, CARMINE

Get full text

Review of adult tracheomalacia and its relationship with chronic obstructive pulmonary disease by Kandaswamy, Chitra, Balasubramanian, Vijay

“…PURPOSE OF REVIEWThis review summarizes the literature on adult or acquired tracheobronchomalacia (TBM) and explores its association with chronic obstructive…”
Get full text

Real-world experience with riociguat as potential bridging therapy in patients with chronic thromboembolic pulmonary hypertension: a case series by Balasubramanian, Vijay P, Beutner, Matthew, Gill, Kirat, Kakol, Monika, Melendres-Groves, Lana

Get full text